Further, joint metabolic‐signaling pathways indicated that pre‐treatment glucose/sugars and FAs/lipids are key metabolites that contribute to cancer progression, whereas post‐treatment p53 signaling and cell cycle regulation are essential pathways that mediate response. Here, TP53 is linked to cancer.